HF Advisory Group LLC Buys 40,738 Shares of Sanofi $SNY

Key Points

• HF Advisory Group LLC boosted its stake in Sanofi by 131.5% in Q4, buying 40,738 shares to own 71,708 shares worth about $3.48 million.
• Other institutions also increased positions (e.g., AQR +107.2% to 30,518 shares; WCG +26.7% to 42,551 shares), with institutional ownership at 14.03% of the stock.
• Sanofi (SNY) trades near $47.73 with a market cap of $116.4B and a P/E of 13.26, and analysts' consensus rating is a "Hold" with a $61.50 price target.

HF Advisory Group LLC grew its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 131.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 71,708 shares of the company's stock after buying an additional 40,738 shares during the quarter. HF Advisory Group LLC's holdings in Sanofi were worth $3,475,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in SNY. Brighton Jones LLC raised its position in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after purchasing an additional 1,869 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company's stock valued at $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company's stock valued at $2,732,000 after purchasing an additional 752 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company's stock valued at $326,000 after buying an additional 347 shares in the last quarter. Finally, WCG Wealth Advisors LLC lifted its position in Sanofi by 26.7% in the 2nd quarter. WCG Wealth Advisors LLC now owns 42,551 shares of the company's stock worth $2,056,000 after buying an additional 8,970 shares during the last quarter. 14.03% of the stock is owned by institutional investors.

Sanofi Price Performance

SNY stock opened at $47.73 on Thursday. The firm's 50-day moving average price is $46.40 and its two-hundred day moving average price is $47.99. Sanofi has a 12-month low of $43.32 and a 12-month high of $55.77. The stock has a market capitalization of $116.41 billion, a price-to-earnings ratio of 13.26, a PEG ratio of 1.20 and a beta of 0.42. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SNY. HSBC reaffirmed a "buy" rating on shares of Sanofi in a research note on Wednesday, December 10th. Wall Street Zen lowered shares of Sanofi from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 21st. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Sanofi in a research note on Monday, December 8th. TD Cowen reaffirmed a "hold" rating on shares of Sanofi in a report on Tuesday, December 30th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Sanofi in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $61.50.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.